Gene Bridges licenses Red/ET Recombineering to Novozymes

Heidelberg, April 21, 2008 - Gene Bridges GmbH, the recombineering company, today announced that Novozymes has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges.

Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications. No financial details were disclosed.

Dr. Alan Berry, Director, Microbial Physiology and HTS at Novozymes Inc. in Davis, CA said: “The Red/ET system is a very powerful technology, and we look forward to using it to accelerate our strain development efforts.”

Dr. Tim Zeppenfeld, Business Development Manager at Gene Bridges GmbH, commented: "We are very pleased to add Novozymes to the list of major industrial biotechnology companies using Red/ET. Recombineering is the technology of choice in metabolic engineering and is used worldwide in industry and academia."

Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome. Recombineering DNA using Red/ET has a number of advantages over conventional methods:

· Independent of restriction sites

· No size limits

· No unwanted mutations

· Rapid

Red/ET Recombineering is one simple and powerful tool to modify plasmids, BACs, and even E.coli chromosomes.

About Gene Bridges GmbH

Gene Bridges GmbH is a self-financed biotech company pioneering recombineering, the fast and precise method of engineering gene sequences. The Company was founded in 2000 as spin-off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Gene Bridges commercialises its patented recombineering technology from its facilities in Heidelberg as well as through its distributors worldwide. Further information can be found by visiting www.genebridges.com .

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com .

Further Information:

Gary Stevens
CEO
Gene Bridges GmbH
t: +49 (0)6221 13708 10
e: gary.stevens@genebridges.com

Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill Life Sciences
t : +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com